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Taher S, Borja Y, Cabanela L, Costers VJ, Carson-Marino M,
Bailes JC, Dhar B, Beckworth MT, Rabaglino MB, Post Uiter-
weer ED, Conrad KP. Cholecystokinin, gastrin, cholecystokinin/
gastrin receptors, and bitter taste receptor TAS2R14: trophoblast
expression and signaling. Am J Physiol Regul Integr Comp Physiol
316: R628–R639, 2019. First published March 20, 2019; doi:10.1152/
ajpregu.00153.2018.—We investigated expression of cholecystokinin
(CCK) in humans and mice, and the bitter taste receptor TAS2R14 in
the human placenta. Because CCK and gastrin activate the CCKBR
receptor, we also explored placental gastrin expression. Finally, we
investigated calcium signaling by CCK and TAS2R14. By RT-PCR,
we found CCK/Cck and GAST/Gast mRNA expression in both normal
human and mouse placentas, as well as in human trophoblast cell lines
(TCL). Although both Cckar and –br mRNA were expressed in the
mouse placenta, only CCKBR mRNA was detected in the human
placenta and TCL. mRNA expression for TAS2R14 was also observed
in the human placenta and TCL. Using immunohistochemistry, CCK
protein was localized to the syncytiotrophoblast (ST) and extravillous
trophoblast (EVT) in the human term placenta, and to trophoblast
glycogen cells in mouse and human placentas. Gastrin and TAS2R14
proteins were also observed in ST and EVT of the human placenta.
Both sulfated and nonsulfated CCK elicited a comparable rise in
intracellular calcium in TCL, consistent with CCKBR expression.
Three TAS2R14 agonists, flufenamic acid, chlorhexidine, and diphen-
hydramine, also evoked rises in intracellular calcium in TCL. These
results establish CCK, gastrin, and their receptor(s) in both human and
mouse placentas, and TAS2R14 in the human placenta. Both CCK
and TAS2R14 agonists increased intracellular calcium in human TCL.
Although the roles of these ligands and receptors, and their potential
cross talk in normal and pathological placentas, are currently un-
known, this study opens new avenues for placental research.
extravillous trophoblast; intracellular calcium; placenta; syncytiotro-
phoblast; trophoblast glycogen cell
INTRODUCTION
In a microarray analysis of first-trimester chorionic villous
samples (CVS; GSE12767), we observed expression of chole-
cystokinin (CCK), which was one of the most highly upregu-
lated genes in CVS from women who later developed pre-
eclampsia compared with women who experienced a normal
pregnancy (9, 28). Interestingly, microarray studies available
in the public domain of delivered placentas (or cytotrophoblast
isolated thereof) from preeclamptic women also demonstra-
ted increased CCK expression relative to normal pregnancy
[GSE40182 (52) and (32)]. In fact, as portrayed in Fig. 1
(previously unpublished), by using bioinformatics approaches
similar to those we earlier described (28), CCK was found to be
one of the few differentially expressed genes in common
between first-trimester CVS and delivered placentas from
women afflicted with preeclampsia. Therefore, we reasoned
that this virtually unique confluence could be more than coin-
cidental, and placental CCK may be of particular biological
significance and worthy of further consideration. CCK mRNA
was previously identified in placentas of women and mice during
genome-wide gene expression profiling and showed increased
expression in cells of unidentified origin in the metrial region of
placentas from diabetic mice by in situ hybridization (37, 39).
Otherwise, to the best of our knowledge, placental CCK has
received little, if any, investigative attention.
Bitter taste receptor (TAS2R) stimuli were recently linked to
CCK secretion in enteroendocrine cells of the gastrointestinal tract
[(6, 13, 14, 49); and DISCUSSION]. We unexpectedly observed
expression of TAS2R14 in our CVS microarray (GSE12767 but
not of other TAS2R genes in the microarray: TAS2R1, TAS2R3–5,
TAS2R7–10, TAS2R13, TAS2R16, TAS2R19, TAS2R38–41,
TAS2R45 or TAS2R50), although TAS2R38 was recently reported
in normal delivered placentas (48). Because of the potential
linkage between CCK and bitter taste receptors, we also set
out to investigate the bitter taste receptor TAS2R14 in the human
placenta.
Admittedly, the work reported herein was mainly discovery
based rather than being hypothesis driven, because it arose
serendipitously in large measure from the tantalizing data
found in microarray analyses (vide supra). Nevertheless, the
specific objectives of this work were a logical extension of the
observations derived from the microarray analyses, and they
were carefully conceived and designed. Specifically, we inves-
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tigated 1) CCK/CCK and TAS2R14/TAS2R14 mRNA and
protein expression in early and late gestational human placen-
tas, and in human trophoblast cell lines; 2) Cck/CCK mRNA
and protein expression in mouse placentas; 3) CCK mRNA
receptor expression (CCKAR/Cckar and –BR/br) in early and
late gestational human placentas, trophoblast cell lines, and in
mouse placentas; and 4) CCK and TAS2R14 calcium signaling
in trophoblast cell lines. Because gastrin (GAST) utilizes
CCKBR as its receptor, we also investigated GAST/GAST
mRNA and protein expression in human placental tissues and
trophoblast cell lines, as well as Gast mRNA in mouse pla-
centa. Although a complete understanding of the physiological
and potential pathophysiological roles of CCK, gastrin, and
TAS2R14, as well as their potential interactions in the placenta
require further investigation, herein we establish CCK, GAST,
and CCK receptor expression by human and mouse tropho-
blasts, TAS2R14 expression by human trophoblasts, and fur-
ther demonstrate that CCK and TASR14 receptor ligands are
both coupled to calcium signaling, CCK mostly, if not exclu-
sively, through CCKBR.
MATERIALS AND METHODS
Human placentas. Human placentas were obtained from uncom-
plicated pregnancies after delivery under Institutional Review Board
(IRB) approval from the University of Florida (IRB 201602330).
Tissue cryosections of first- and second-trimester placentas were
provided by the National Institutes of Health Placental Bank at the
University of California San Francisco (NICHD/NIH HD055764)
under IRB approval from the University of Florida (IRB 201600936).
Human trophoblast cell lines. Trophoblast cell lines were propa-
gated in T75 flasks at 37°C under standard tissue culture conditions
(5% CO2-balance room air). The HTR-8/SVneo trophoblast cell line
derived from first-trimester human villous trophoblasts was gener-
ously provided by Dr. Charles Graham, Queens University (12). We
previously corroborated the trophoblast origin of these cells in our
laboratory (26). HTR-8/SVneo cells were cultured in T75 flasks
containing complete media: RPMI 1640 with glucose (2.0 g/l), L-glu-
tamine (0.3 g/l), and sodium bicarbonate (2.0 g/l). JAR, JEG, and
BeWo choriocarcinoma cells are trophoblast derived and they were
purchased from the American Type Culture Collection. JAR cells
were cultured in the same media as described for the HTR-8/SVneo
cells. JEG cells were cultured in EMEM containing L-glutamine (0.3 g/l)
and sodium pyruvate (0.1 g/l). BeWo cells were propagated in F12
Nutrient Mixture Kaighn’s Modification with L-glutamine (0.3 g/l).
All media were supplemented with penicillin (100 U/ml), streptomy-
cin (100 g/ml; Sigma, St. Louis, MO, or Corning, Mediatech,
Manassas, VA), and 10% FBS (GE Healthcare Life Sciences, Hyclone
Laboratories).
Mouse placentas. Placentas were harvested from pregnant C57BL/6J
mice of 13.5, 14.5, 15.5, and 17.5 gestational days under Institutional
Animal Care and Use Committee approval from University of Florida
(IACUC 201508950).
RT-PCR. Total RNA was extracted from placental tissues and
trophoblast cell lines using TRI Reagent (Ambion/ThermoFisher
Scientific) according to the manufacturer’s instructions and then
dissolved in RNA secure solution (Ambion/ThermoFisher Scientific).
RNA was treated with DNase (Ambion/Thermo Fisher Scientific) to
remove any contaminating genomic DNA. The yield and purity of the
resulting RNA preparations were determined by NanoDrop spectro-
photometer. Total RNA from mouse placenta (E17) was obtained
Fig. 1. Overlap of differentially expressed genes (DEG) between preeclamptic (PE) and normal pregnancies in chorionic villous samples (CVS) and delivered
placentas. A and B: PE-CTB, DEG between cytotrophoblasts isolated from villous placentas delivered by women with severe PE (PE-CTB) relative to gestational
age-matched preterm (noninfected) controls (52; GSE40182); PE-CVS, DEG between CVS from women who developed severe PE relative to normal pregnancy
outcome (28; GSE12767). Twenty-five DEG overlapped between the CVS and PE-CTB, but only 8 DEG changed in the same direction in the CVS and PE-CTB;
CCK was upregulated in both. C and D: PE-villous, DEG between villous tissue from placentas delivered by women with PE compared with normal pregnancy
controls (data obtained from Table II in Ref. 32); PE-CVS. Five DEG overlapped between the CVS and villous tissue from delivered placentas with only 2
changing in the same direction, one of which was CCK that was upregulated.
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from Zyagen (San Diego, CA), and human brain cortex, stomach, and
duodenum RNA were purchased from Clontech Laboratories (Mountain
View, CA). First-strand cDNA was synthesized using the SuperScript III
First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) or
M-MLV Reverse Transcriptase (Promega, Madison, WI) and Oligo
(dT15) primers (Promega) according to the manufacturer’s instruc-
tions. PCR was performed with 1 l of cDNA in a 19-l reaction
containing (final concentration) 1 Green Go Taq Flexi Buffer, 1.5
mM MgCl2, 0.2 mM of each dNTP, 0.4 M each of forward and
reverse primers, and 0.5 units GoTaq DNA Polymerase per reaction
(Promega). Intron or exon/exon-spanning primers were designed us-
ing OligoPerfect (Invitrogen/ThermoFisher Scientific) or Primer-Blast
(NCBI-NIH), and synthesized by Integrated DNA Technologies (Cor-
alville, IA) (see Supplemental Table S1; all supplemental material can
be accessed on the journal website). Twenty to forty cycles were
performed on a Mastercycler Gradient PCR machine (Eppendorf,
Hauppauge, NY) at 94°C for 30 s, 50–60°C for 1 min, and 72°C for
1 min with an initial 3 min at 80°C and a final 10 min at 72°C. PCR
products were then electrophoresed on 1–2% agarose gels containing
ethidium bromide or GelRed (ThermoFisher Scientific) and visualized
under UV light using a VersaDoc system (Bio-Rad, Hercules, CA). A
100-bp DNA ladder (ThermoFisher Scientific) was run on each gel.
For negative controls, nuclease-free water was substituted for RT or
nuclease-free water replaced the cDNA in the PCR reaction.
Immunohistochemistry. Human villous and decidual basal plate
tissues from normal delivered placentas, and whole mouse placentas
including decidua were fixed in fresh 4% phosphate-buffered formalin
for 18–24 h at 4°C followed by decanting and then three rinses in 10
ml ice-cold PBS for 10 min each on ice using a magnetic stir bar. The
tissues were stored in 70% ethanol at 4°C until further processing.
After being embedded in paraffin, 4-m-thick sections were cut from
the tissue blocks and transferred to SuperFrost Plus slides (Thermo-
Fisher Scientific). After drying, the slides were deparaffinized in
xylene and ethanol solutions. The sections were next dried for 5 min
before permeabilization with 0.3% Triton X-100 and quenching of
endogenous peroxidase with 1% hydrogen peroxide in methanol.
After blocking of the sections with 1.5% normal horse serum, the
sections were incubated with the primary or non-immune isotype
antibody overnight at 4°C in a humidified chamber. In some instances,
the primary antibody was preabsorbed with blocking peptide as an
additional negative control. Supplemental Table S2 contains the list of
primary and nonimmune isotype antibodies used in each figure or
supplemental figure. The Supplemental Methods, including Supple-
mental Figs. S1 and S2, provide further details about the primary
antibodies.
On the following day, the sections were incubated with a secondary
anti-goat or anti-mouse/anti-rabbit biotinylated antibody for 30 min at
room temperature in a humidified chamber. Immunodetection was
subsequently performed using a Vectastain ABC Elite kit and DAB
Peroxidase Substrate Kit (both from Vector Laboratories, Burlingame,
CA). After dehydration of the sections in ethanol and xylene solutions,
they were sealed with coverslips using Cytoseal XYL (ThermoFisher
Scientific). The immunostained sections were visualized using an Olym-
pus BX41 System Microscope (Olympus, Tokyo, Japan), photographed
with an Olympus DP71 Microscope Digital Camera, and saved with DP
Controller and Manager.
The early placental human placental cryosections were warmed to
room temperature and fixed for 20 min with 4% phosphate-buffered
formalin followed by three rinses in PBS. Thereafter, the procedures
were identical to those described above.
Intracellular calcium. After reaching confluence in the T75 flasks,
the trophoblast cell lines were passaged into 35-mm glass bottom petri
dishes (MatTek, Ashland, MA). When the cells were 75–90% con-
fluent, they were rinsed once with DPBS containing Ca2/Mg2, and
then incubated in 0.1% Pluronic F-127 containing 5.0 g/ml (4.6 M)
of Fluo 4-AM (ThermoFisher Scientific) in physiological saline so-
lution (PSS: 140 mM NaCl, 5.0 mM KCl, 1.5 mM CaCl2, 1.0 mM
MgCl2, 10 mM glucose, 10 mM HEPES, and 0.1% wt/vol BSA) for
25 min at 37°C. The cells were then rinsed three times with PSS and
the dishes placed on a heated stage of the fluorescent microscope.
Baseline fluorescence (480-nm excitation, 535-nm emission) was
measured for 60 s followed by the addition of sulfated CCK (sCCK)
or nonsulfated cholecystokinin (CCK). Alternatively, three agonists of
TAS2R14 were introduced, either chlorohexidine (CHLX), flufe-
namic acid (FFA), or diphenhydramine (15, 16, 24, 33). The calcium
ionophore A23187 was used as a positive control. Fluorescent inten-
sity was subsequently measured for an additional 4 min. The fluores-
cent signal was captured with a Nikon Eclipse Ti-E Inverted Fluores-
cent Microscope (Nikon Instruments, Melville, NY) using a Andor
Zyla sCMOS Monochrome Camera (Andor Technology, Belfast,
UK). The signals were subsequently analyzed using Nikon NIS-
Elements software. The fluorescent excitation source was a Lumencor
Spectra X Light Engine (Lumencor, Beaverton, OR).
RESULTS
RT-PCR: mRNA expression. Because our objective was to
detect mRNA expression, we used standard RT-PCR. Human
placental villous and decidual basal plate tissues, as well as two
trophoblast cell lines expressed CCK mRNA as determined by
two different primer pair sets (Fig. 2A, top and middle). Mouse
placenta (E.17) expressed Cck mRNA, predominantly variant
1 as assessed by two different primer pair sets (Fig. 2B, left and
right). Variant 2 was faintly detected with one of the primer
pair sets (Fig. 2B, right). Either CCKBR variant 1, variant 2, or
both mRNAs (but not CCKAR mRNA; data not shown) were
weakly expressed by human placental villous and decidual
basal plate tissues, as well as by trophoblast cell lines as
measured by partial nested primer RT-PCR (Fig. 2C). In
contrast, both Cckbr and –ar mRNA were detected in mouse
placenta (E.17) using either one primer pair set or nested
primer pairs (Fig. 2D, left and right, respectively). Figure 3A
(top and middle) shows TAS2R14 and GAST mRNA expres-
sion, respectively, in human placental villous and decidual
basal plate tissues, as well as two trophoblast cell lines. Finally,
gast mRNA was also detected in the E.17 mouse placenta (Fig.
3B).
Immunohistochemistry: protein expression. We identified
CCK expression using two different CCK antibodies, one
directed against the COOH-, and another against the NH2-
terminus. Importantly, these CCK antibodies were generated
against human peptide sequences spanning amino acids 50–
100 (“COOH”-terminus) and 20–70 (“NH2”-terminus) each
with little or no overlap with preprogastrin: 7/50 and 8/50
amino acids, respectively. These antibodies did not discrimi-
nate among the numerous active CCKs generated by proteol-
ysis of the 115-amino acid prepropeptide; however, such dis-
crimination was not an objective of this work and will be the
subject of future investigation. In contrast, there is marked
homology of human and mouse CCK such that 44/50 and
35/50 amino acids were overlapping for recognition of mouse
CCK by the COOH- and NH2-terminus antibodies, respec-
tively.
With the use of the CCK antibody directed against the
COOH-terminus, CCK (Fig. 4A, a, c, e, and g) was colocalized
with cytokeratin (Fig. 4Ah), demonstrating expression by syn-
cytiotrophoblasts (ST) and extravillous trophoblasts (EVT) in
normal human term placenta (n  5 placentas). CCK staining
was inhibited by preabsorption with the COOH-, but not
NH2-terminus-blocking peptide, the latter serving as another
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control (Fig. 4A, d and f, respectively). CCK expression in ST
and EVT was corroborated using the CCK antibody directed
against the NH2-terminus (Fig. 4B). CCK was also expressed
by EVT and ST in early gestational placentas (n  10 placen-
tas; Fig. 4C and 6C, and Supplemental Fig. S3, respectively).
In normal human term placenta, there was colocalization of
CCK (Fig. 5A, a and e) and cytokeratin (Fig. 5A, b and f) with
periodic acid-Schiff-positive, glycogen-expressing trophoblast
cells (Fig. 5A, c and g), although many trophoblast cells express-
ing glycogen did not express CCK and vice versa. Similar coin-
cidences of CCK, cytokeratin, and periodic acid-Schiff staining
were observed in trophoblast glycogen cells located in the
mouse junctional zone and decidua (Fig. 5B, a, b, and c,
respectively). Finally, neither CCK-AR nor –BR was detect-
able by immunohistochemistry in human or mouse placenta
(data not shown).
In addition to CCK, GAST was also expressed in ST and
EVT of normal human term placenta (n  4 placentas; Fig.
6A). Importantly, the antibody for human GAST, which was
directed against amino acids 1–13, showed minimal overlap with
CCK: 4/13 amino acids. The bitter taste receptor TAS2R14 was
detected by immunohistochemistry in EVT of normal human
term placenta identified by cytokeratin staining (n  5 placen-
tas) using two different antibodies (Fig. 6Ba, rabbit polyclonal
anti-TAS2R14 antibody; Fig. 6Bf, goat polyclonal anti-
TAS2R14 antibody). Many, but not all EVT expressing
TAS2R14 also coexpressed CCK (Fig. 6Bd). TAS2R14 was
also detected in ST (see Supplemental Fig. S3C) and EVT of
early gestation human placentas and colocalized with CCK at
least in some EVT (Fig. 6C; n  2 placentas). However,
because of the limited number of early-gestation placental
sections available for investigation of TAS2R14 expression,
additional studies are needed.
Fluo 4 calcium-sensitive dye: calcium signaling. As a point
of reference, 1.0 M A23187, a calcium ionophore, increased


















Fig. 2. A: expression of cholecystokinin (CCK) mRNA by human placenta and trophoblast cell lines using RT-PCR. Top: one primer pair yielded an amplicon
with a predicted size of 185 bp. Middle: a second primer set yielded an amplicon with a predicted size of 103 bp. Bottom: actin  (ACTB, 807 bp). See
Supplemental Table S1A for details of human primer sets. 3rd, third trimester; 1st, first trimester; V, villous; BP, basal plate; 1, 2, 3, 3 different placentas;
JEG, JEG choriocarcinoma cells; HTR-8, HTR-8/SVneo immortalized 1st-trimester extravillous trophoblast cells; Hu Br Cortex, human brain cortex (positive
control); NFW, nuclease-free water substituted for cDNA in the PCR (negative control); BP ladder, base pair ladder (bright band of 500 bp). B: expression of
Cck mRNA by mouse placenta (E.17) using RT-PCR. Left: one primer pair yielded an amplicon with a predicted size of 429 bp consistent with Cck variant 1
(V1). However, using the same primer pair, an amplicon with a predicted size 529 bp for Cck variant 2 (V2) was absent. Actb (807 bp). Right: using a second
primer set unique for Cck V1 yielded an amplicon with a predicted size of 211 bp, and a faint band of 364 bp was obtained using another primer set specific
for Cck V2. See Supplemental Table S1B for details of mouse primer sets.  and – RT, with and without reverse transcriptase. C: expression of CCKBR receptor
mRNA by human placenta and trophoblast cell lines using RT-PCR. Partial nested primer PCR revealed amplicons of predicted size of 557 and 809 bp for
CCKBR V2 and CCKBR V1, respectively. D: expression of Cckar and -br receptor mRNA by mouse placenta (E.17) using RT-PCR. Left: outer primer pairs
for Cckar and –br yielded amplicons of predicted size, i.e., 433 and 220 bp, respectively. Right: amplicons generated using the outer primer pairs were
subsequently amplified with inner primer pairs producing amplicons of predicted size for Cckar and –br, respectively, 264 and 198 bp. There were 2 higher,
unidentified bands generated by the Cckar nested primer reaction. Actb (807 bp).
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100% of cells responding. Both nonsulfated and sulfated CCK
stimulated rises in intracellular calcium in JEG cells (Fig. 7, A
and B, respectively). The equimolar doses of sulfated and
nonsulfated CCK (10 nM) elicited a comparable increase,
suggesting a predominant action through CCKBR. A selective
CCKBR antagonist (YM-022) was more effective in blocking
the calcium response than a selective CCKAR antagonist
(devazepide) (7); see Supplemental Fig. S4). Sulfated CCK
was also tested in two other trophoblast cells lines, JAR and
BeWo, but the fold-increase in intracellular calcium and the
percentage of responding cells were less than for JEG cells
(Fig. 7, C and D). Interestingly, neither 10 nM (n  9 dishes)
or 1.0 M (n  6 dishes) sulfated CCK increased intracellular
calcium in the HTR-8/SVneo trophoblast cell line (data not
shown).
The TAS2R14 agonist FFA (10, 30, and 100 M) increased
intracellular calcium in a more or less dose-responsive fashion
in JEG cells both in regard to the maximum calcium response
and percentage of responding cells (Fig. 8A, a–c). FFA also
increased intracellular calcium in JAR, BeWo, and HTR-8/
SVneo trophoblast cell lines (Fig. 8A, d–g). The calcium
response to FFA was replicated by another TAS2R14 agonist,
CHLX (10 M) (Fig. 8B). However, the pattern of increase
was gradual and not immediate for the JEG and HTR-8/SVneo
cells. Lower CHLX concentrations of 1.0 and 3.0 M failed to
increase intracellular calcium in any of the four cell lines (n 
3 dishes each; data not shown). Yet diphenhydramine, another
TAS2R14 agonist, also increased intracellular calcium in JAR
cells. A concentration of 0.25 mM did not raise intracellular
calcium (data not shown), being below the threshold dose in
JAR cells of 0.5 mM with the maximum stimulus being 1.0
mM (see Supplemental Fig. S5) The DMSO vehicle for FFA
and CHLX, when diluted to the same degree as 30 and 100 M
FFA, did not affect intracellular calcium (n  2 dishes each;
data not shown).
DISCUSSION
CCK: ligands, receptors, and cell signaling. Major findings
were that CCK mRNA was expressed in third-trimester villous
and decidual basal plate of placentas delivered following nor-
mal pregnancies, and in first-trimester villous. CCK mRNA
was observed in choriocarcinoma and HTR-8/SVneo cell lines.
CCK protein was detected in the ST and EVT of early-
gestation and normal delivered placentas, the latter using two
different antibodies, one directed against a COOH-terminus
peptide and the other against a NH2-terminus peptide (with









Fig. 3. A: expression of human TAS2R14, gastrin (GAST), and
actin  (ACTB) mRNA by human placenta and trophoblast cell
lines using RT-PCR. Top: RT-PCR for TAS2R14 generated an
amplicon of predicted size, 518 bp. Middle: RT-PCR for GAST
resulted in an amplicon with the predicted size of 242 bp.
Bottom: ACTB (807 bp). See Supplemental Table S1A for
details of human primer sets. 3rd, third trimester; 1st, first
trimester; V, villous; BP, basal plate; JEG, JEG choriocarci-
noma cells; HTR-8, HTR-8/SVneo immortalized 1st-trimester
extravillous trophoblast cells; Hu Duod, human duodenum
(positive control);  and – RT, with and without reverse
transcriptase; BP ladder, base pair ladder (bright band of 500
bp). B: expression of Gast mRNA by mouse placenta (E.17)
using RT-PCR. RT-PCR generated an amplicon of predicted
size, 211 bp. Actb (807 bp). See Supplemental Table S1B for
details of mouse primer sets. NFW, nuclease free water substi-
tuted for cDNA in the PCR reaction (negative control).
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mRNA was readily detected in mouse placenta, and protein
expression was also observed, predominantly in trophoblast
glycogen cells located in the junctional zone and decidua.
Finally, CCKBR/br, but not –AR/ar receptor mRNA, was
detected at low levels in human placenta, and both receptor
mRNAs were expressed in the mouse placenta. CCK receptors
were not detected in the placenta of either species by immu-
nohistochemistry, most likely because of low expression of
these GPCRs and/or ineffective antibodies.
Another major observation was that sulfated and nonsulfated
CCK stimulated increases in intracellular calcium in human
trophoblast cell lines. Equimolar doses of sulfated and nonsul-
fated CCK elicited comparable increases in intracellular cal-
cium and percentage of responding cells, suggesting a predom-
inate action through CCKBR, because nonsulfated CCK has a
much lower affinity than sulfated CCK for CCKAR, whereas
their affinities for CCKBR are comparable (7). The concept
that CCKBR is the major receptor mediating CCK calcium
signaling was further supported by data showing that a
CCKBR antagonist, YM-022, completely blocked the calcium
response, whereas a CCKAR antagonist, devazepide, was only
partly effective (7). Finally, CCKBR, but not –AR mRNA was
detected in human placenta and trophoblast cell lines. A caveat
is that at the higher concentrations of CCK, YM-022, and
devazepide used in the antagonist protocol, this experiment by
itself was not definitive. However, by taking into consideration
the other evidence (vide supra), the primacy of the CCKBR
receptor is likely.
Interestingly, CCK elicited calcium signaling in all three
choriocarcinoma cell lines, but not in the HTR-8/SVneo cells.
In future studies, primary cytotrophoblasts require interroga-
tion. The nanomolar concentrations of CCK needed to consis-
tently stimulate increases in intracellular calcium were high
compared with circulating levels that are in the picomolar
range (10, 29). Nevertheless, CCK concentration could be high
in the immediate vicinity of placental ST and EVT, or the
placental CCKBR might be a low-affinity receptor. Because
CCK is expressed by trophoblasts, and trophoblasts respond to
CCK by increasing intracellular calcium (at least in choriocar-
cinoma cell lines), these results suggest an autocrine role for
CCK, which remains to be further elucidated. By analogy to
other cell systems, CCK might stimulate acetylcholine release
from trophoblasts, which is highly expressed in this cell type,
or upregulate the ABCB1 transporter (4, 13, 27, 38). Tropho-
blast CCK could also play a vasodilatory role (4), and have
other paracrine or even endocrine roles. For example, both
directly (21, 25, 35, 36, 51) and indirectly through acetylcho-
line release (3, 30, 46), CCK might exert immunomodulatory
actions at the maternal-fetal interface. Finally, because fasting
plasma CCK increases during pregnancy (10) [although not all
agree (29)], it is not inconceivable that the placenta might





















Fig. 4. A: localization of cholecystokinin (CCK)
protein in syncytiotrophoblast and extravillous tro-
phoblasts of normal delivered human placenta us-
ing an antibody directed against the COOH-termi-
nus (100 magnification). a, c, e, and g: Immuno-
staining with COOH-terminus CCK antibody. b:
Goat IgG, negative control. d: COOH-terminus
CCK antibody preabsorbed with CCK COOH-ter-
minus blocking peptide, f: COOH-terminus CCK
antibody preincubated with CCK NH2-terminus
blocking peptide. h: Cytokeratin 18 (CYT) anti-
body. Arrows indicate cells colocalizing with CCK
and cytokeratin 18. B: localization of CCK protein
in syncytiotrophoblast and extravillous trophoblasts
of normal delivered human placenta using an anti-
body directed against the NH2-terminus (100
magnification). a and c: Immunostaining with NH2-
terminus CCK antibody. b: Goat IgG, negative
control. d: Cytokeratin 18 antibody. Arrows indi-
cate cells colocalizing with CCK and cytokeratin
18. C: localization of CCK protein in extravillous
trophoblast of early-gestation human placenta (15.4
wk). a–d: 100 Magnification. e–h: 400 Magni-
fication. a and e: Immunostaining with COOH-
terminus CCK antibody. b and f: Goat IgG, nega-
tive control. c and g: Cytokeratin 18 antibody. d
and h: Mouse IgG, negative control.
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The mechanism for CCK production and/or secretion by
trophoblasts is unknown. We tried unsuccessfully to detect
basal and stimulated sulfated CCK in conditioned media and
lysates of choriocarcinoma cells and villous explants using
an RIA specific for the sulfated form (ALPCO, Salem, NH;
data not shown). We attempted to stimulate CCK production
by raising intracellular calcium using A23187, BAY K
8644, methacholine, and TAS2R14 receptor agonists, as
well as by augmenting intracellular cAMP with dibutyryl
cAMP and human chorionic gonadotropin. We added pro-
tease inhibitors to the media to mitigate catabolism of CCK,
if it was being secreted, and concentrated the conditioned
media. However, these procedures did not result in detect-
able sulfated CCK either. However, as a positive control, we
were able to measure sulfated CCK in the conditioned media
of STC-1 cells, which possess many features of native
mouse intestinal enteroendocrine cells (ATCC CRL-3254)
(41, 42, 47). In contrast, we detected low levels of nonsul-
fated CCK in the conditioned media of JEG, HTR-8/SVneo,
and STC-1 cells, but not villous explants by EIA (RayBio-
tech, Norcross, GA; data not shown). However, after further
inquiry, we found that this assay did not distinguish non-
sulfated CCK from gastrin, because the antibody was made
against a homologous peptide in the C-terminus. Thus,
whether nonsulfated CCK, gastrin, or both were detected
cannot be distinguished. The reason for not readily detecting
sulfated CCK in the conditioned media is also unclear,
because the cells are clearly expressing CCK (vide supra).
One possibility is that secretion rates are extremely low, and
therefore undetectable by our RIA in the conditioned me-
dium. Another potential explanation is that nonsulfated
CCK may be the major form(s) produced by trophoblasts,
consistent with the expression of CCKBR and not –AR (31).
Yet another potential reason is that appropriate stimuli for
CCK secretion were not used. For example, in the gut, CCK
is released by various fatty acids through the ILDR1, CD-
36, GPR120, and GPR40 receptors (5, 22, 41, 42), and
amino acids through a CaSR receptor (47). Finally, although
entirely speculative, it is possible that CCK is not secreted,















Fig. 5. A: localization of cholecystokinin (CCK)
protein and periodic acid-Schiff (PAS) staining in
trophoblast cells of normal delivered human pla-
centa (400 magnification). a and e: immuno-
staining with COOH-terminus CCK antibody. b
and f: Cytokeratin 19 (CYK) antibody. c and g:
PAS staining. d and h: Goat IgG, negative control.
Arrows indicate cells colocalizing with CCK, cy-
tokeratin 19, and PAS. B: colocalization of CCK
protein and PAS staining in glycogen trophoblast
cell of 16.5-day gestation mouse placenta (100
magnification). a: Immunostaining with COOH-
terminus CCK antibody. b: Cytokeratin 19 anti-
body. c: PAS staining. GC, glycogen cells.
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Gastrin. In the literature, whether gastrin mRNA was ex-
pressed in human or mouse placenta is contentious (18, 40, 50,
52). On the other hand, gastrin protein was detected using
radioimmunoassay in a homogenate prepared from delivered
placenta(s) (1). Because we identified CCKBR/br mRNA in
both human and mouse placenta, we expanded our initial
investigation to include gastrin, which interacts with CCKBR.
Not only did we find abundant GAST mRNA in first-trimester
villous, third-trimester villous, and decidual basal plate and
trophoblast cell lines, we also identified mRNA expression in
mouse placenta. Protein expression was observed in both ST
and EVT of healthy, delivered human placenta. Because the
gastrin antibody we used was specific for humans, we did not
explore gastrin protein expression in mouse placenta.
TAS2R14. While conducting our work on placental TAS2R14,
a report emerged showing TAS2R38 expression by immunohis-
tochemistry specifically in the chorion layer of human fetal
membranes, but not in ST or decidua basalis as we report
herein for TAS2R14. TAS2R38 was also expressed by JEG
cells, which responded to the TAS2R38 agonist phenylthiocar-
bamide by increasing intracellular calcium (48). In our work,
TAS2R14 mRNA was expressed in first-trimester villous and
decidua basalis, third-trimester villous and decidual basal plate,
































Fig. 6. A: localization of gastrin protein in syncy-
tiotrophoblast and extravillous trophoblast of nor-
mal delivered human placenta (a–c: 100 magni-
fication; d–f: 400 magnification). a and d: Im-
munostaining with gastrin antibody. b and e:
Cytokeratin 18 (CYT) antibody. c and f: Mouse
IgG, negative control. Circles and arrows indicate
cells colocalizing with gastrin and cytokeratin 18.
B, top: localization of TAS2R14 protein in ex-
travillous trophoblast of normal delivered human
placenta (100 magnification). a: Immunostain-
ing with rabbit polyclonal TAS2R14 antibody. b:
Cytokeratin 19 (CYK) antibody. c: Rabbit IgG,
negative control. Bottom: colocalization of
TAS2R14 and CCK protein in extravillous tro-
phoblast of normal delivered human placenta
(400 magnification). d: Immunostaining with
COOH-terminus CCK antibody. e: Cytokeratin 19
antibody. f: Goat polyclonal TAS2R14 antibody.
Arrows indicate cells colocalizing with CCK,
TAS2R14, and cytokeratin 19. C: localization of
TAS2R14, CCK, and cytokeratin in extravillous
trophoblast of early gestation human placenta.
Top: a–c: 100 magnification. Bottom: d–f: 400
magnification. a and d: Immunostaining with cy-
tokeratin 18 antibody. b and e: COOH-terminus
CCK. c and f: Goat polyclonal TAS2R14
antibody.
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ST and EVT in term and early-trimester placentas, although
further study of early-trimester placenta is needed due to
limited availability of these tissues for TAS2R14 immunohis-
tochemistry. Many, but not all EVT coexpressed CCK and
TAS2R14 in the term and early-gestation placentas. Because
TAS2R14 is a specific human taste receptor, we did not
investigate mouse placenta in parallel as we did for CCK,
CCKAR, and –BR and gastrin. To our knowledge, expression
of TAS2R14 in the human placenta has not been previously
reported. Nevertheless, sweet and bitter taste receptors outside
of the oral cavity are being identified in a growing number of
organs including the kidney, thyroid, and heart; however, the
physiological and pathophysiological consequences remain in-
completely understood or speculative (23).
FFA (10 nM-30 M) and CHLX (0.1–1.0 M) specifically
increase intracellular calcium expression in HEK-293T cells
transfected with a plasmid harboring TAS2R14, but not with
other human taste receptors (24). It should be pointed out,
however, that the maximum concentrations of FFA and CHLX
which activate TAS2R14 without increasing intracellular cal-
cium nonspecifically, i.e., independently of TAS2R or activat-
ing other TAS2R receptors besides TAS2R14, were not clearly
delineated in the report of Meyerhof et al. (24). Nevertheless,
we found that for FFA, intracellular calcium was increased in
the choriocarcinoma cell lines and in HTR-8/SVneo cells using
concentrations that fell within the range of concentrations
reported to be specific for TAS2R14 (vide supra). For CHLX,
however, a higher concentration of 10 M was required to
elicit an increase in intracellular calcium. Inexplicably, the
pattern of change in intracellular calcium was not consistent for
the two TAS2R14 agonists in JEG and HTR-8/SVneo cells
with FFA eliciting the usual robust increase, in contrast to
CHLX, which produced a gradual rise.
As intimated above, the TAS2R14 agonists are likely to
have off-target effects, e.g., FFA may exert other actions (8).
Nevertheless, we used two other agonists of the TAS2R14
receptor, CHLX and diphenhydramine (15, 16, 24, 33), and
these also increased cytosolic calcium in trophoblast-derived
cells. Although we cannot exclude additional alternative mech-
anisms for raising intracellular calcium, one target that all three
agonists do have in common is the TAS2R14 receptor.
As with CCKAR- and BR, the physiological or pathophys-
iological roles of trophoblast TAS2R14 are presently unknown
and require exploration in future investigations. By analogy to
other systems, TAS2R14 may detect harmful chemicals in the
circulation that otherwise would produce a “bitter taste” in the
oral cavity, although it is difficult to conceive of how such
compounds could reach sufficient concentrations in the mater-
nal blood to be effective. Nevertheless, activation of TAS2R38
expressed by enteroendocrine cells in the gut, presumably by
bitter taste compounds that are not completely expectorated,
leads to secretion of CCK that, in turn, upregulates ABCB1
transporters in neighboring enteric cells, leading to extrusion of
the noxious compound into the gut lumen, thereby limiting
intestinal absorption (13). Conceivably, a similar mechanism,
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Fig. 7. Intracellular calcium of trophoblast-derived choriocarcinoma cells in response to cholecystokinin (CCK). Values are means 	 SE of dishes analyzed
depicted in the main figure. Insets: results for each dish, in which intracellular calcium was averaged for only responding cells. A: JEG cells (n  3 dishes) treated
with 10 nM nonsulfated CCK. The percentage of responding cells was 86.2 	 7.0%. B: JEG cells (n  7 dishes) treated with 10 nM sulfated CCK. Responding
cells: 86.2 	 4.9%. C: JAR cells (n  8 dishes) treated with 1.0 M sulfated CCK. Responding cells: 38.6 	 6.9%. D: BeWo cells (n  7 dishes) treated with
1.0 M sulfated CCK. Responding cells: 31.4 	 9.1%.
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Fig. 8. A: intracellular calcium of trophoblast-derived choriocarcinoma cells in response to the TAS2R14 receptor agonist flufenamic acid (FFA). Values are
means 	 SE of dishes analyzed as depicted in the main figure. Insets: results for each dish, in which intracellular calcium was averaged for only responding cells.
JEG cells were treated with FFA in a, 10 M, n  4 dishes; b: 30 
, n  9 dishes; and c: 100 M, n  5 dishes. Percentages of responding cells were
49.5 	9.9, 76.8 	 9.2, and 94.4 	 4.9%, respectively. JAR cells were treated with FFA in d, 30 M, n  6 dishes and e: 100 M, n  7 dishes. Percentages
of responding cells were 24.1 	 8.5 and 94.3 	 4.1%, respectively. BeWo and HTR8 cells, respectively, were treated with FFA in f, 30 M, n  4 dishes and
g, 100 M, n  6 dishes. Percentages of responding cells were 53.8 	 10.3 and 93.9 	 2.4%, respectively. B: intracellular calcium of trophoblast-derived
choriocarcinoma cells in response to the TAS2R14 receptor agonist chlorhexidine (CHLX; 10 M). Values are means 	 SE of all dishes analyzed as depicted
in the main figure. Insets: results for each dish, in which intracellular calcium was averaged for only responding cells. a: JAR cells (n  4 dishes). Percentage
of responding cells was 87.0 	 5.0%. b: JEG cells (n  7 dishes). Responding cells: 70.2 	 8.6%. c: BeWo cells (n  5 dishes). Responding cells: 63.6 	 7.3%.
d: HTR8 (n  6 dishes). Responding cells: 59.5 	 5.3%. No responses were observed with lower concentrations of 1.0 or 3.0 M.
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ultimately protecting the placenta, and thus, the fetus from
potentially harmful chemicals. Indeed, the placenta is a rich
source of ABC transporters (2, 44). Other possible roles relate
to immunological function. For example, TAS2R14 activation
was shown to increase antimicrobial peptide secretion in the
human airway (20). By analogy, a similar pathway may exist in
the placenta, which is a rich source of antimicrobial peptides
(17). In addition, there is an emerging literature suggesting that
bitter taste receptors are targets of microbial products leading
to stimulation of the innate immune system and other protec-
tive mechanisms (19, 43, 45). Thus, again by analogy,
TAS2R14 and other potential taste receptors expressed by
placental ST and EVT might recognize bacterial quorum-
sensing molecules, thereby contributing to interkingdom com-
munication within the placenta (11, 34).
In summary, we identified CCK, gastrin, and their recep-
tor(s) in both human and mouse placenta. Furthermore, bitter
taste receptor TAS2R14 was also observed in the human
placenta. We demonstrated expression of these molecules by
ST and extravillous trophoblasts. These conclusions were
based upon parallel mRNA and protein expression by RT-PCR
and immunohistochemistry, respectively, and demonstration of
calcium signaling using CCK and TAS2R14 agonists in human
trophoblast cell lines. The precise functions of these ligands
and receptors, as well as their potential interactions in the
normal and pathological placenta are currently unknown, but
the possibilities are numerous and intriguing. This study opens
new and unexplored avenues of placental investigation.
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